Prognostic significance and targeting of HER family in colorectal cancer.

  title={Prognostic significance and targeting of HER family in colorectal cancer.},
  author={Said Abdullah Khelwatty and Sharadah Essapen and Alan Michael Seddon and Helmout Modjtahedi},
  journal={Frontiers in bioscience},
Colorectal cancer is one of the leading causes of cancer deaths. At present, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) cetuximab and panitumumab and anti-vascular endothelial growth factor (VEGF) mAb bevacizumab have been incorporated into treatment paradigms for patients with refractory metastatic colorectal cancer. However, many patients simply do not respond to these treatments or eventually acquire resistance following a short course therapy. In this article… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 13 extracted citations

Radiolabeled F(ab′)2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2018
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 238 references

An update on the current and emerging targeted agents in metastatic colorectal cancer

E. Chu
Clinical Colorectal Cancer, 11, 1-13 • 2012

Cancer statistics, 2012.

CA: a cancer journal for clinicians • 2012

Similar Papers

Loading similar papers…